New Treatment For Age-Related Macular Degeneration Within Sight

With 8 million people at high risk for advanced age-related Macular Degeneration, researchers from Harvard and Japan discovered that the   experimental drug, endostatin, may be the cure. A research report    describes how giving endostatin to mice significantly reduced or   eliminated abnormal blood vessel growth within the eye, which is   ultimately why the disease causes blindness.

"Our study provides intriguing findings that may lead to a better   treatment of age-related Macular Degeneration," said Alexander Marneros,   the first author of the report, "but clinical studies in patients with   age-related Macular Degeneration are still necessary."

In this study, researchers describe testing the effects of endostatin   on mice lacking this naturally occurring substance. The mice without   endostatin were about three times more likely to develop advanced   age-related Macular Degeneration (AMD) than normal mice. Then the   researchers administered endostatin to both sets of mice. In the mice   lacking endostatin, the number of abnormal blood vessels that cause AMD   were reduced to normal levels. In control mice with normal levels of   endostatin, the number of abnormal blood vessels were practically   undetectable.

"With Baby Boomers reaching advanced ages, new treatments are   desperately needed to keep age-related Macular Degeneration from   becoming a national epidemic," said Gerald Weissmann, MD,   Editor-in-Chief of The FASEB Journal. "This research provides hope for   those at risk for blindness, and it gives everyone another glimpse of   how investments in molecular biology will ultimately pay off in terms of   new treatments and cures."

AMD is a progressive disease that affects the part of the eye that   allows people to see fine details. The disease gradually destroys sharp,   central vision, and in advanced stages ultimately leads to total   blindness. Abnormal blood vessel growth, also known as angiogenesis, is a   hallmark of advanced AMD. These faulty blood vessels leak fluids and   blood, causing catastrophic vision loss.


As the name implies, risk for age-related Macular Degeneration   increases with age, and 8 million people are considered to be at high   risk for the disease. Of these individuals, approximately 1 to 1.3   million will develop advanced AMD within the next five years. Endostatin   is an experimental drug, which is currently being tested to stop cancer   in people by restricting the formation of abnormal blood vessels supply   blood to tumors. Endostatin is a protein in collagen, and while   collagen is used in a range of products for skin care to gelatin   desserts, consumption or use of these products does not have any effect   on tumors or AMD.

Weissmann added, "This research proves once and for all that   endostatin functions as the body's own natural inhibitor of new blood   vessel growth as Judah Folkman of Harvard predicted."

This research was published in the December 2007 issue of The FASEB Journal.

http://www.sciencedaily.com/releases/2007/11/071129142449.htm

Story Source:

  The above story is reprinted from materials provided by Federation of American Societies for Experimental Biology, via EurekAlert!, a service of AAAS.

  Note: Materials may be edited for content and length. For further information, please contact the source cited above.